Table 2.
Effects of oral JBD0131 on hematological parameters in male SD rats (Day 15)
| Parameter | Control group | Vehicle group | 50 mg/kg group | 150 mg/kg group | 500 mg/kg group | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | Mean ± SD | n | Mean ± SD | n | Mean ± SD | n | Mean ± SD | n | Mean ± SD | |
| WBC (109/L) | 5 | 5.12 ± 1.21 | 5 | 5.35 ± 0.75 | 5 | 5.80 ± 1.36 | 5 | 6.53 ± 2.36 | 5 | 5.94 ± 2.48 |
| NEU% (%) | 5 | 12.8 ± 3.2 | 5 | 9.8 ± 2.4 | 5 | 8.5 ± 2.1 | 5 | 12.3 ± 3.8 | 5 | 11.8 ± 3.8 |
| LYM % (%) | 5 | 83.3 ± 3.4 | 5 | 86.4 ± 3.0 | 5 | 87.9 ± 2.5 | 5 | 83.9 ± 3.5 | 5 | 84.7 ± 3.9 |
| MONO% (%) | 5 | 1.4 ± 0.1 | 5 | 1.2 ± 0.4 | 5 | 1.3 ± 0.4 | 5 | 1.5 ± 0.5 | 5 | 1.2 ± 0.3 |
| EOS% (%) | 5 | 0.68 ± 0.37 | 5 | 0.80 ± 0.20 | 5 | 0.60 ± 0.14 | 5 | 0.72 ± 0.22 | 5 | 0.54 ± 0.23 |
| BASO% (%) | 5 | 0.06 ± 0.09 | 5 | 0.12 ± 0.04 | 5 | 0.08 ± 0.04 | 5 | 0.10 ± 0.00 | 5 | 0.02 ± 0.04 |
| NEU (109/L) | 5 | 0.63 ± 0.03 | 5 | 0.51 ± 0.11 | 5 | 0.48 ± 0.10 * | 5 | 0.74 ± 0.15 | 5 | 0.63 ± 0.02 |
| LYM (109/L) | 5 | 4.29 ± 1.14 | 5 | 4.64 ± 0.77 | 5 | 5.11 ± 1.31 | 5 | 5.54 ± 2.16 | 5 | 5.11 ± 2.38 |
| MONO (109/L) | 5 | 0.07 ± 0.02 | 5 | 0.06 ± 0.01 | 5 | 0.08 ± 0.01 | 5 | 0.10 ± 0.05 | 5 | 0.07 ± 0.05 |
| EOS (109/L) | 5 | 0.032 ± 0.013 | 5 | 0.040 ± 0.007 | 5 | 0.034 ± 0.005 | 5 | 0.042 ± 0.019 | 5 | 0.030 ± 0.007 |
| BASO (109/L) | 5 | 0.002 ± 0.004 | 5 | 0.004 ± 0.005 | 5 | 0.006 ± 0.005 | 5 | 0.004 ± 0.005 | 5 | 0.002 ± 0.004 |
| RBC (1012/L) | 5 | 6.90 ± 0.29 | 5 | 6.85 ± 0.25 | 5 | 7.62 ± 0.54 * | 5 | 6.72 ± 0.33 | 5 | 6.86 ± 0.38 |
| HGB (g/L) | 5 | 139 ± 6 | 5 | 140 ± 4 | 5 | 149 ± 5 * | 5 | 136 ± 4 | 5 | 137 ± 4 |
| HCT (%) | 5 | 42.4 ± 1.7 | 5 | 42.4 ± 1.1 | 5 | 46.1 ± 1.7 * | 5 | 41.7 ± 1.6 | 5 | 41.9 ± 1.3 |
| MCV (fL) | 5 | 61.4 ± 2.1 | 5 | 61.9 ± 2.2 | 5 | 60.6 ± 2.4 | 5 | 62.1 ± 1.3 | 5 | 61.2 ± 1.9 |
| MCH (pg) | 5 | 20.1 ± 0.8 | 5 | 20.4 ± 0.6 | 5 | 19.6 ± 0.8 | 5 | 20.3 ± 0.4 | 5 | 20.0 ± 0.8 |
| MCHC (g/L) | 5 | 328 ± 4 | 5 | 330 ± 3 | 5 | 324 ± 3 | 5 | 327 ± 2 | 5 | 327 ± 8 |
| PLT (109/L) | 5 | 947 ± 49 | 5 | 950 ± 61 | 5 | 1036 ± 102 | 5 | 963 ± 103 | 5 | 907 ± 70 |
| RET% (%) | 5 | 3.20 ± 0.43 | 5 | 3.02 ± 0.38 | 5 | 3.11 ± 0.62 | 5 | 3.06 ± 0.27 | 5 | 3.12 ± 0.44 |
| RET (1012/L) | 5 | 0.220 ± 0.025 | 5 | 0.207 ± 0.028 | 5 | 0.235 ± 0.039 | 5 | 0.205 ± 0.013 | 5 | 0.216 ± 0.027 |
| APTT (sec) | 5 | 9.9 ± 2.2 | 5 | 9.5 ± 0.7 | 5 | 8.7 ± 1.6 | 5 | 7.9 ± 1.2 | 5 | 9.7 ± 1.2 |
| PT (sec) | 5 | 9.1 ± 0.4 | 5 | 9.1 ± 0.5 | 5 | 8.9 ± 0.4 | 5 | 9.0 ± 0.4 | 5 | 9.0 ± 0.4 |
Neutrophils (NEU) are indicated as NEUT in the Pristima system; lymphocytes (LYM) are indicated as LYMPH; reticulocyte count and percentage (RET and RET%) are indicated as RETIC and %RETIC, respectively. * indicates a statistically significant difference from the control group (P ≤ 0.05)
WBC White blood cells, NEU% neutrophil percentage, LYM% lymphocyte percentage, MONO% monocyte percentage, EOS% eosinophil percentage, BASO% basophil percentage, NEU neutrophil count, LYM lymphocyte count, MONO monocyte count, EOS eosinophil count, BASO basophil count, RBC red blood cells, HGB hemoglobin, HCT hematocrit, MCV mean corpuscular volume, MCH mean corpuscular hemoglobin, MCHC mean corpuscular hemoglobin concentration, PLT platelets, RET% reticulocyte percentage, RET reticulocyte count, APTT activated partial thromboplastin time, PT prothrombin time